| Related Articles |
The effect of using Fidaxomicin on recurrent Clostridium difficile infection?
J Hosp Infect. 2019 Jan 04;:
Authors: Biggs M, Iqbal T, Holden E, Clewer V, Garvey MI
Abstract
Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/18 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% patients responded to treatment when fidaxomicin was given during the first episode of a mild CDI. Conversely, all patients with recurrent CDI (rCDI) failed treatment with fidaxomicin. There were mixed results with using fidaxomicin for severe CDI, with only 42% of patients responding. Our results suggest fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.
PMID: 30615960 [PubMed - as supplied by publisher]